Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

키워드

참고문헌 (13)

1. Craig AJ, "Tumour evolution in hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 17, pp.139~152 (2020)
2. Singal AG, "Epidemiology and surveillance for hepatocellular carcinoma : new trends", J Hepatol, 72, pp.250~261 (2020)
3. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
4. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 noninferiority trial", Lancet, 391, pp.1163~1173 (2018)
5. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
6. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
7. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
8. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
9. Cheol-Hyung Lee, "Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment", Clinical and Molecular Hepatology, 26(3), pp.328~339 (2020), 대한간학회[DOI]
10. Yoo C, "Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma", Invest New Drugs, 37, pp.567~572 (2019)
11. Ellis AR, "Approaches to inverse-probability-oftreatment--weighted estimation with concurrent treatments", J Clin Epidemiol, 66(8 Suppl), pp.S51~S56 (2013)
12. Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, doubleblind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
13. Liao W, "Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma", Liver Int, 39, pp.2408~2416 (2019)

관련 논문AI추천